|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The response of mycorrhizal colonization to elevated CO2 and climate change in Pascopyrum smithii and Bouteloua gracilis 显示文摘 | Monz C A Hunt H W Reeves F B | 1994 | Plant Soil1994，165，： | 1 |
| 2 | Sexual problems and distress in United States women: Prevalence and correlates显示文摘 | Shifren J L Monz B U Russo P A | 2008 | Obstet Gynecol2008，112，5： | 1 |
| 3 | Development andvalidation of a cough and sputum assessment questionnaire 显示文摘 | Crawford B Monz B Hohlfeld J | 2008 | Respir Med2008，102，11： | 1 |
| 4 | Patient characteris- tics associated with quality of life in European women seeking treat- ment for urinary incontinence: results from PURE显示文摘 | Monz B Chartier- Kastler E Hampel C | 2007 | Eur Urol2007，51，4： | 1 |
| 5 | Development and validation of a cough and sputum assessment questionnaire显示文摘 | Crawford B Monz B Hohlfeld J | 2008 | Respir Med2008，102，11： | 1 |
| 6 | Modulation of trophoblast function by tumor necrosis f actor-alpha: A role in pregnancy establishment and maintenance显示文摘 | Monz N B Feinberg V O | 2002 | Am J Obstet Gyneeol2002，187，： | 1 |
| 7 | General preferences for involvement in treatment decision making among European women with urinary incontinence 显示文摘 | M OD Monz B Hunskaar S | 2007 | Soc Sci Med2007，64，9： | 1 |
| 8 | Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence显示文摘 | Monz B Kasder EC Hampel C | | 0，，： | 1 |
| 9 | Cost effectiveness of tiotrepi- um for chronic obstructive pulmonary disease: a systematic review of the evidence 显示文摘 | Mauskopf J A Baker C L Monz B U | 2010 | J Med Econ2010，13，3： | 1 |
| 10 | Proliferation and oxygenation status of WiDr spheroids in different lactate and oxygen environments显示文摘 | B Monz U Karbach K Groebe and W | 1996 | Oncol Rep1996，1，： | 1 |
| 11 | Patient characteristics associated with quality of life in european women seeking treatment for urinary incontinence:Results from PURE显示文摘 | Monz B Chartier K E Hampel C | 2007 | European Urology2007，51，4： | 1 |
| 12 | Quality of life outcomes among patients with depression after 6 months of starting treatment:results from FINDER显示文摘 | Reed C Monz B U Perahia D G | 2009 | J Affect Disord2009，113，3： | 1 |
| 13 | Induced pluripotent stem cells as suitable sensors for fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome显示文摘BACKGROUND Fibromyalgia(FM)and myalgic encephalomyelitis/chronic fatigue syndrome(ME/CFS)are devastating metabolic neuroimmune diseases that are difficult to diagnose because of the presence of numerous symptoms and a lack of specific biomarkers.Despite patient heterogeneity linked to patient subgroups and variation in disease severity,anomalies are found in the blood and plasma of these patients when compared with healthy control groups.The seeming specificity of these“plasma factors”,as recently reported by Ron Davis and his group at Stanford University,CA,United States,and observations by our group,have led to the proposal that induced pluripotent stem cells(iPSCs)may be used as metabolic sensors for FM and ME/CFS,a hypothesis that is the basis for this indepth review.AIM To identify metabolic signatures in FM and/or ME/CFS supporting the existence of disease-associated plasma factors to be sensed by iPSCs.METHODS A PRISMA(Preferred Reported Items for Systematic Reviews and Meta-analysis)-based systematic review of the literature was used to select original studies evaluating the metabolite profiles of FM and ME/CFS body fluids.The MeSH terms“metabolomic”or“metabolites”in combination with FM and ME/CFS disease terms were screened against the PubMed database.Only original studies applying omics technologies,published in English,were included.The data obtained were tabulated according to the disease and type of body fluid analyzed.Coincidences across studies were searched and P-values reported by the original studies were gathered to document significant differences found in the disease groups.RESULTS Eighteen previous studies show that some metabolites are commonly altered in ME/CFS and FM body fluids.In vitro cell-based assays have the potential to be developed as screening platforms,providing evidence for the existence of factors in patient body fluids capable of altering morphology,differentiation state and/or growth patterns.Moreover,they can be further developed using approaches aimed at blocking or reversing the effects of specific plasma/serum factors seen in patients.The documented high sensitivity and effective responses of iPSCs to environmental cues suggests that these pluripotent cells could form robust,reproducible reporter systems of metabolic diseases,including ME/CFS and FM.Furthermore,culturing iPSCs,or their mesenchymal stem cell counterparts,in patient-conditioned medium may provide valuable information to predict individual outcomes to stem-cell therapy in the context of precision medicine studies.CONCLUSION This opinion review explains our hypothesis that iPSCs could be developed as a screening platform to provide evidence of a metabolic imbalance in FM and ME/CFS. | María B Monzón-Nomdedeu Karl J Morten Elisa Oltra | 2021 | World Journal of Stem Cells2021，13，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员